Abbott AM, et al. - Researchers assessed the hepatic progression-free survival (HPFS), progression-free survival (PFS), and overall survival (OS) following regional therapy to the liver for metastatic melanoma. Significantly prolonged HPFS and PFS were seen in patients treated with percutaneous hepatic perfusion (PHP) vs chemoembolization (CE) or yttrium-90 (Y90). In patients treated with PHP, median OS was over double than seen in patients treated with Y90 or CE, however, it was significant only between PHP and Y90. On multivariate analysis, significant predictors of prolonged PFS were PHP treatment and lower tumor burden.